1. Career Development in Translational Addiction Research
Jacqueline F. McGinty, Ph.D.
Interim Dean, College of Graduate Studies
NIDA T32 Director
Dept. of Neuroscience and
Neurobiology of Addiction Research Center
Medical University of South Carolina

2. Career Development in Drug Abuse Research
“Fellows on NRSA grants, compared with their colleagues without NRSA support, are more likely to be appointed as faculty and more likely to apply for and receive independent NIH support.”
NIDA Mentoring Guide
Predoctoral T32->F30/F31
Postdoctoral T32->F32
K Awards
NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12)
PAR (K12) - March 28, 2013
NIH Pathway to Independence Award (Parent K99/R00)
PA (K99/R00) - December 19, 2013
Mentored Quantitative Research Development Award (Parent K25)
PA (K25) - December 19, 2013
Mentored Patient-Oriented Research Career Development Award (Parent K23)
PA (K23) - December 19, 2013
Mentored Clinical Scientist Research Career Development Award (Parent K08)
PA (K08) - December 19, 2013
Mentored Research Scientist Development Award (Parent K01)
PA (K01) - December 19, 2013
Independent Scientist Award (Parent K02)
PA (K02) - December 19, 2013

3. Competing applications, awards, and success rates
Data and chart description for this slide can be located at 3

4. Competing applications, awards, and success rates
Data and chart description for this slide can be located at 4

5. Research Career Development Awards
Data and chart description for this slide can be located at 5

6. Research Career Development Award Success Rates

7. NIDA Mentoring Guide
"NIDA offers a strategic set of funding mechanisms to support the development of research scientists through various stages of their careers. These awards are designed to ensure that scientists of the very highest caliber will be available in adequate numbers and in the appropriate research areas and fields to meet the Nation's drug abuse and addiction needs."
– Nora D. Volkow, M.D., NIDA Director
The guide was developed over several years with the help of both mentors and mentees. Work began at a workshop of the College on Problems of Drug Dependence (CPDD) in 2003, continued at a career development seminar of CPDD in 2005, and culminated at the National Institute on Drug Abuse (NIDA) Research Training Institute in 2006.

8. NIDA Strategic Plan
The current NIDA Strategic Plan was published in Since that time, there have been major advances in the science of drug abuse and addiction. In the Strategic Plan for 2016–2020, NIDA seeks to harness the latest research technologies and apply them to the ever-evolving substance abuse landscape. Toward this goal, NIDA staff developed a draft set of strategic priorities and are seeking feedback to guide the development of NIDA’s Strategic Plan.
See more at:

9. NIDA Strategic Priorities 2016-2020
Basic Neuroscience: Improve our understanding of the basic science of drug use, addiction, vulnerability to addiction, and recovery
Increase our knowledge of biological, behavioral, environmental, and developmental factors involved in risk and resilience for drug use and addiction
Integrating animal models, behavior, genetics, epigenetics, and other molecular biomarkers for drug abuse and addiction
Understand the developmental trajectory of addiction and individual heterogeneity
Improve our understanding of brain circuits related to drug abuse and addiction at the cellular, circuit, and connectome levels, including:
Normal development and function across the lifespan including mechanisms of reward, self-control, and conditioning
Drug effects on neuroplasticity, neural structure, and circuit function across the stages of addiction
Neurobiological correlates of recovery
Neural-glial, -immune, and neuroendocrine interactions
Better define the interactions between addiction and pain, including molecular, genetic, behavioral , and neural-circuit-related factors, to guide the development of alternate treatment strategies for pain patients
Improve our understanding of the interaction between addiction and co-occurring conditions
Elucidate the impact of mental health, HIV, HCV, pain, etc. on addiction;
Understand molecular mechanisms of latent HIV reservoirs in the brains of substance-abusing populations
See more at:

10. NIDA Strategic Priorities 2016-2020
Clinical and Translational Science: Support the development of new and better interventions and treatments that incorporate the diverse needs of individuals with Substance Use Disorders (SUDs)
Support the development of novel, evidence-based, targeted prevention and treatment interventions including social, behavioral, pharmacological, vaccines, and brain stimulation therapies (e.g., transcranial magnetic stimulation, direct current stimulation, etc.)
Accelerate the identification of promising targets and ligands to accelerate new drug discovery and development
Accelerate medications development for SUDs
Focused development efforts on:
Addictions without an FDA approved treatment
Detoxification
Overdose prevention or reversal
Accelerating neurobiological recovery
Addressing comorbidities (MH, HIV, HCV, pain)
Develop techniques to measure and improve patient compliance in clinical trials
Identify measures other than abstinence that can reliably assess SUD treatment outcomes Identify biomarkers of addiction, resilience, and recovery to enable personalized treatment
See more at:

11. NIDA Strategic Plan 2016-2020 DIVERSITY:
The demographics of students and mentees are changing continually. As the demographic characteristics of mentees shift, so must the training of mentors.
NOT-OD 
 Date: January 12, 2015
Purpose
The purpose of this notice is to provide an updated diversity statement that describes NIH's interest in the diversity of the NIH-funded workforce.
NEED FOR TEAM SCIENCE:
Approaches from single disciplines have done much to advance drug abuse research, but technological, methodological, and other advances have established the need for increasingly multidisciplinary approaches to address more complex questions.

12. Trends in race/ethnicity of NIH-supported Ph.D. recipients
White
Data and chart description for this slide can be located at
Hispanic
Asian/Pacific Islander
Black 12

13. BIOMEDICAL RESEARCH WORKFORCE WORKING GROUP REPORT
National Institutes of Health
June 14, 2012

14. US Graduate Degrees Awarded, by Field
MDs
Basic Biomedical

15. Years Biomedical PhDs Spend in Postdoctoral Training
Most US-trained biomedical PhDs spend fewer than 5 years in postdoctoral positions, although that number has been grown since 2003

16. Biomedical Postdoctoral Researchers by Type of Support

17. Age at First PhD, First Non Postdoctoral Job, First Tenure Track Job, for US trained Doctorates
First non-postdoc Job
First PhD

18. Distribution of NIH RPG Principal Investigators by Degree Type
PhD MD
MD/
PhD
Researchers with an MD or MD/PhD comprise around 30% of NIH-funded Principal Investigators (PIs). The percentage of MDs has declined and the percentage of MD/PhDs has increased slightly in the past few years.

19. Estimated Change in Employment Levels in Biomedical Occupations
Medical Scientists
Postsecondary
Teachers
Biological Scientists
Biochemists
Survey of Doctorate Recipients

20. Biomedical PhD Job Stats

21. McGinty Lab